SelectQuote, Inc. filings document formal disclosures for a public insurance distribution and healthcare services company. Recent Form 8-K reports furnish quarterly and annual operating results, investor presentation exhibits, and segment information for Senior, Healthcare Services, Life, and SelectRx-related activity.
The company’s regulatory filings also cover capital-structure matters, including a senior secured credit facility and revolving credit facility, as well as NYSE continued-listing compliance disclosures. Governance records include annual meeting voting results for director elections, auditor ratification, and advisory executive-compensation matters, while amended event reports document corrections to previously furnished earnings materials.
SelectQuote, Inc. chief operating officer William Thomas Grant III reported multiple equity transactions on August 1, 2026. He exercised previously granted RSUs and price-vested RSUs into 525,328 shares of common stock and had 174,642 shares withheld at $0.747 per share for taxes. He also received new grants of 500,000 restricted stock units and 500,000 price-vested restricted stock units (PVUs) with multi-year service and stock-price hurdles, and reported indirect holdings through a trust, Haakon Capital, LLC, and an IRA.
SelectQuote general counsel Daniel Allen Boulware reported multiple equity compensation transactions. On August 1, 2026 he exercised restricted and price-vested stock units into 217014 shares of common stock at $0.00 per share, with 91909 shares withheld at $0.747 for taxes. He also received grants of 218750 restricted stock units and 218750 price-vested units that vest over time and depend on stock-price performance targets, and holds 1100 shares indirectly through his spouse.
BlackRock, Inc. files an Amendment No. 6 to Schedule 13G/A reporting beneficial ownership of 2,104,967 shares of SelectQuote, Inc. common stock. The filing shows 2104967 shares representing 1.2% of the class as of 06/30/2026. The cover lists CUSIP 816307300 and the filing is signed by Spencer Fleming on 07/08/2026.
SelectQuote, Inc. director Denise L. Devine reported an open-market sale of 4,000 shares of common stock on May 19, 2026 at a weighted average price of $1.02 per share. After this transaction, she directly holds 367,214 shares of SelectQuote common stock.
SelectQuote, Inc. reported solid third‑quarter fiscal 2026 results, with consolidated revenue of $430.9 million and net income of $40.2 million, both up from the prior year period. Adjusted EBITDA rose to $44.6 million, reflecting stronger profitability.
The Senior segment generated revenue of $182.9 million and Adjusted EBITDA of $58.6 million, helped by 175,557 approved Medicare Advantage policies and a favorable $14 million change in estimate to commissions receivable. Healthcare Services produced revenue of $199.4 million, Adjusted EBITDA of $5.3 million, and served 116,616 SelectRx members.
Life segment revenue reached $47.9 million with Adjusted EBITDA of $6.1 million. On a rolling 12‑month basis, total revenue per Medicare Advantage/Medicare Supplement policy was $2,490 and the revenue‑to‑customer‑acquisition‑cost multiple improved to 6.7x. The company reaffirmed full‑year 2026 guidance, targeting revenue of $1.61–$1.71 billion and Adjusted EBITDA of $90–$100 million.
SelectQuote, Inc. reported that it received a notice from the New York Stock Exchange stating its common stock no longer meets the NYSE’s $1.00 minimum average closing price requirement over a consecutive 30 trading-day period. The company has six months from March 19, 2026 to regain compliance.
SelectQuote plans to notify the NYSE of its intent to cure the deficiency, monitor its share price and, if needed, pursue actions that may require stockholder approval, such as potential corporate actions affecting the share price. During the cure period, its shares remain listed on the NYSE, assuming compliance with all other listing standards.
In the accompanying press release, the company highlighted a new $415 million credit facility extending most debt maturities to 2031 and projected fiscal 2026 operating cash flow of $25 million to $35 million, which it believes supports liquidity while it works to maintain its NYSE listing.
SelectQuote, Inc. director Chris Wolfe reported acquiring shares through equity compensation. On February 28, 2026, he exercised or converted restricted stock units, acquiring 9,502 shares of common stock at a price of $0.00 per share.
The filing also shows 9,502 restricted stock units tied to this transaction, with 19,006 restricted stock units held after the transaction and 9,502 common shares held directly. These awards were granted under SelectQuote’s 2020 Omnibus Incentive Plan and vest in three annual installments, subject to continued Board service.
SelectQuote, Inc. Chief Financial Officer Clement Ryan Moore reported equity award activity involving restricted stock units and common shares. On February 28, 2026, restricted stock units covering 20,834 shares were converted into an equal number of common shares, and 7,219 common shares were surrendered at $0.86 per share to cover tax withholding obligations. On March 1, 2026, an additional 6,234 restricted stock units were converted into 6,234 common shares, with 2,161 common shares surrendered at $0.86 per share for taxes. After these transactions, Moore directly held 322,393 shares of SelectQuote common stock. The restricted stock units were granted under the company’s 2020 Omnibus Incentive Plan and each unit represents a contingent right to receive one common share, vesting in three- or four-year annual installments, subject to continued employment.